Nexalin Technology unveils next-generation HALO Clarity

Nexalin Technology unveiled its Gen-3 HALO neurostimulation device designed to treat a variety of mental health conditions, including Major Depressive Disorder, addiction and substance use disorder, Alzheimer’s disease, traumatic brain injury, post-traumatic stress disorder, chronic pain and other potentially-applicable stress-related neuropsychiatric disorders. Mark White, CEO of Nexalin Technology, stated, “The HALO Clarity marks a significant advance and possibly the most meaningful event in the history of the Company. When we established Nexalin and embarked on this journey, we set out to develop a first-in-class neurostimulation device, superior to anything currently available in the market. The HALO Clarity represents the culmination of years of research, testing and product development. I truly believe this device will revolutionize how we treat mental health disorders in the United States and around the world.”